{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T22:35:42Z","timestamp":1774478142281,"version":"3.50.1"},"reference-count":23,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2001,4,1]]},"abstract":"<jats:p> PURPOSE: Standard chemotherapy for advanced ovarian cancer currently includes a platinum agent (usually carboplatin) and paclitaxel. Because docetaxel is an active agent in platinum-resistant ovarian cancer, it is relevant to evaluate both the toxicity and efficacy of the combination of carboplatin and docetaxel in this clinical setting. <\/jats:p><jats:p> PATIENTS AND METHODS: The Gynecologic Oncology Program of the Cleveland Clinic Taussig Cancer Center conducted a phase II trial of carboplatin (area under the concentration-versus-time curve of 6) and docetaxel (60 mg\/m<jats:sup>2<\/jats:sup>), delivered every 3 weeks for six courses, in patients with ovarian and fallopian tube cancers and primary carcinoma of the peritoneum who had either received no prior chemotherapy or had experienced a treatment-free interval of greater than 2 years before developing disease recurrence. <\/jats:p><jats:p> RESULTS: Fifty patients (median age, 57 years; range, 44 to 81 years) entered the trial (47 had had no prior chemotherapy). Our toxicity findings included the following: grade 4 neutropenia (64% of patients); hypersensitivity reactions (34%, none requiring discontinuation of therapy); peripheral neuropathy (6%). We had objective responses for 32 of 42 (81%) assessable patients. <\/jats:p><jats:p> CONCLUSION: The combination of carboplatin and docetaxel is highly active in ovarian cancer, with the major toxicity being bone marrow suppression. Hypersensitivity reactions are frequent but do not prevent continuation of treatment. With the dose and schedule employed in this trial, neurotoxicity is uncommon. Defining a role for this regimen in routine clinical practice will require the conduct of randomized controlled clinical trials. <\/jats:p>","DOI":"10.1200\/jco.2001.19.7.1901","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:41:13Z","timestamp":1487918473000},"page":"1901-1905","source":"Crossref","is-referenced-by-count":75,"title":["Combination Chemotherapy With Carboplatin and Docetaxel in the Treatment of Cancers of the Ovary and Fallopian Tube and Primary Carcinoma of the Peritoneum"],"prefix":"10.1200","volume":"19","author":[{"given":"Maurie","family":"Markman","sequence":"first","affiliation":[{"name":"From the Gynecologic Cancer Program, The Cleveland Clinic Taussig Cancer Center, and the Departments of Gynecology\/Obstetrics and Hematology\/Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kennedy","sequence":"additional","affiliation":[{"name":"From the Gynecologic Cancer Program, The Cleveland Clinic Taussig Cancer Center, and the Departments of Gynecology\/Obstetrics and Hematology\/Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Webster","sequence":"additional","affiliation":[{"name":"From the Gynecologic Cancer Program, The Cleveland Clinic Taussig Cancer Center, and the Departments of Gynecology\/Obstetrics and Hematology\/Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gertrude","family":"Peterson","sequence":"additional","affiliation":[{"name":"From the Gynecologic Cancer Program, The Cleveland Clinic Taussig Cancer Center, and the Departments of Gynecology\/Obstetrics and Hematology\/Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Kulp","sequence":"additional","affiliation":[{"name":"From the Gynecologic Cancer Program, The Cleveland Clinic Taussig Cancer Center, and the Departments of Gynecology\/Obstetrics and Hematology\/Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Belinson","sequence":"additional","affiliation":[{"name":"From the Gynecologic Cancer Program, The Cleveland Clinic Taussig Cancer Center, and the Departments of Gynecology\/Obstetrics and Hematology\/Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-086666","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601043340101"},{"key":"R2-086666","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.9.699"},{"key":"R3-086666","unstructured":"Ozols  RF,   Bundy  BN,   Fowler  J,  et al:  Randomized phase III study of cisplatin(CIS)\/paclitaxel(PAC) versus carboplatin(CARBO)\/PAC in optimal stage III epithelial ovarian cancer(OC):   A Gynecologic Oncology Group trial (GOG 158).   Proc Am Soc Clin Oncol 18:  356a,1999  (abstr 1373)"},{"key":"R4-086666","unstructured":"du Bois  A,   Lueck  HJ,   Meier  W,  et al:  Cisplatin\/paclitaxel vs. carboplatin\/paclitaxel in ovarian cancer:   Update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Trial.   Proc Am Soc Clin Oncol 18:  356a,1999  (abstr 1374)"},{"key":"R5-086666","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.5-1-26"},{"key":"R6-086666","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2301"},{"key":"R7-086666","doi-asserted-by":"crossref","unstructured":"Kaye  SB,   Piccart  M,   Aapro  M,  et al:  Docetaxel in advanced ovarian cancer:   Preliminary results from three phase II trials.   Eur J Cancer 31A:  S14,1995-S17,     (suppl 4)","DOI":"10.1016\/0959-8049(95)00361-L"},{"key":"R8-086666","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.9.676"},{"key":"R9-086666","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.14.2733"},{"key":"R10-086666","unstructured":"Guastalla  JP,   Ferrero  J-M,   Dieras  V,  et al:  Cisplatin-docetaxel (Taxotere) in first line treatment of advanced ovarian cancer (OC):   A GINECO phase II trial.   Proc Am Soc Clin Oncol 18:  375a,1999  (abstr 1448)"},{"key":"R11-086666","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2069"},{"key":"R12-086666","doi-asserted-by":"crossref","unstructured":"Meyer  A,   Huober  JB,   Goerner  R,  et al:  Chemotherapy with carboplatin\/docetaxel for primary and recurrent epithelial ovarian cancer.   Proc Am Soc Clin Oncol 18:  379a,1999  (abstr 1465)","DOI":"10.1016\/S0959-8049(99)81386-0"},{"key":"R13-086666","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1996.0210"},{"key":"R14-086666","doi-asserted-by":"publisher","DOI":"10.1007\/s004320000157"},{"key":"R15-086666","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.10.2643"},{"key":"R16-086666","doi-asserted-by":"publisher","DOI":"10.1007\/s004320050346"},{"key":"R17-086666","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1998.5065"},{"key":"R18-086666","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.7.1589"},{"key":"R19-086666","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2426"},{"key":"R20-086666","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.193"},{"key":"R21-086666","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(93)90169-G"},{"key":"R22-086666","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010719"},{"key":"R23-086666","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008211203563"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2001.19.7.1901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:31:08Z","timestamp":1653514268000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2001.19.7.1901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4,1]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2001,4,1]]}},"alternative-id":["10.1200\/JCO.2001.19.7.1901"],"URL":"https:\/\/doi.org\/10.1200\/jco.2001.19.7.1901","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,4,1]]}}}